ATS 2019 Virtual Final Program

Chairing: T. Lahm, MD, Indianapolis, IN P.M. Hassoun, MD, Baltimore, MD I.S. Douglas, MD, Denver, CO 2:15 Introduction T. Lahm, MD, Indianapolis, IN 2:20 Epidemiology and Phenotypes of RV Failure: What Have We Learned in the Last 10 Years and What Do We Need to Learn in the Next 5 Years? S.M. Kawut, MD, MS., Philadelphia, PA 2:40 Pathogenesis of RV Failure: What Do We Know and What Do We Need to Know? F. de Man, PhD, Amsterdam, Netherlands 3:00 Diagnosis and Risk Stratification of RV Failure: How Can We Get to Where We Need to Be? J. Leopold, MD, Boston, MA 3:20 Treatment of RV Failure: Are We Closer to Developing RV-Targeted Therapies? A. Hemnes, MD, ATSF, Nashville, TN 3:40 Acute RV Failure in the ICU: A Distinct Phenotype that Warrants Further Study? I.S. Douglas, MD, Denver, CO 4:00 Discussion CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 MOC Points Available: 2 A88 RETHINKING OXYGEN: GETTING THE RIGHT OXYGEN TO THE RIGHT PATIENT Assemblies on Nursing; Behavioral Science and Health Services Research; Pulmonary Rehabilitation 2:15 p.m. - 4:15 p.m. KBHCCD Room D162/D164 (Level 1) Target Audience This symposium will benefit health care professionals who care for adults who use supplemental oxygen therapy. Objectives At the conclusion of this session, the participant will be able to: • identify unmet needs and barriers to oxygen delivery in patients with COPD, ILD, and rare lung diseases, including young people who require supplemental oxygen; • understand impact of oxygen delivery on the quality of life in patients with lung disease and their caregivers; • identify the role of advocacy for rare lung disease and the implications for policy change for our patients who use supplemental oxygen therapy. Pulmonary clinicians and patients report barriers in providing and receiving optimal home supplemental oxygen services including inadequate supply, unacceptable portable options, equipment malfunction, absence of quality measures, and lack of evidence-based practice guidelines. Limited evidence exists to describe or quantify these problems and to address these unmet needs. This session will provide information on the variation of oxygen use in patients with COPD and ILD, impact of oxygen on quality of life for patients and caregivers, existing evidence for our practice today, importance of advocacy for patients with rare lung diseases and young adults requiring oxygen, and the role of policy in best helping our patients. Chairing: K.O. Lindell, PhD, RN, ATSF, Pittsburgh, PA S.S. Jacobs, RN, MS, Stanford, CA 2:15 Introduction and Opening Remarks S.S. Jacobs, RN, MS, Stanford, CA 2:25 A Patient's Perspective H. Kagel, Dallas, TX 2:30 Oxygen for COPD: Knowns and Unknowns J.A. Krishnan, MD, PhD, ATSF, Chicago, IL 2:50 Oxygen and ILD C.J. Ryerson, MD, Vancouver, Canada 3:10 Quality of Life for Oxygen Users and their Caregivers J.J. Swigris, DO, MS, Denver, CO 3:25 Impact of Supplemental Oxygen in Patients with Interstitial Lung Disease: Findings of the Mixed Method AmbOx Trial M. Farquhar, PhD, RN, Norwich, United Kingdom 3:40 Advocacy in Rare Lung Disease: When Oxygen is Not Optional S. Sherman, BS, MHA, Cincinnati, OH 3:55 Implications for Policy G. Ewart, MHS, Washington, DC 4:10 Conclusion: Moving Forward K.O. Lindell, PhD, RN, ATSF, Pittsburgh, PA CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 MOC Points Available: 2 A89 COMMUNITY-ACQUIRED PNEUMONIA 2019: AN INTERACTIVE SESSION Assemblies on Pulmonary Infections and Tuberculosis; Clinical Problems; Critical Care 2:15 p.m. - 4:15 p.m. KBHCCD Ballroom A Three (Level 2) Target Audience Clinicians, researchers, and administrative physicians, nurses, advanced practice clinicians, pharmacists, and respiratory therapists who provide care for patients with pneumonia Objectives At the conclusion of this session, the participant will be able to: • learn 2019 best treatment of patients with community-acquired pneumonia; • have new strategies to manage the care of pneumonia patients, replacing HCAP logic with more effective measures for identifying patients at risk for antibiotic resistant pathogens; ATS 2019 • Dallas, TX 102 SUNDAY • MAY 19